` RNXT (RenovoRx Inc) vs S&P 500 Comparison - Alpha Spread

RNXT
vs
S&P 500

Over the past 12 months, RNXT has underperformed S&P 500, delivering a return of +10% compared to the S&P 500's +13% growth.

Stocks Performance
RNXT vs S&P 500

Loading
RNXT
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
RNXT vs S&P 500

Loading
RNXT
S&P 500
Difference
www.alphaspread.com

Performance By Year
RNXT vs S&P 500

Loading
RNXT
S&P 500
Add Stock

Competitors Performance
RenovoRx Inc vs Peers

S&P 500
RNXT
ABBV
AMGN
GILD
VRTX
Add Stock

RenovoRx Inc
Glance View

Market Cap
47.5m USD
Industry
Biotechnology

RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for the local treatment of solid tumors. The company is headquartered in San Jose, California and currently employs 6 full-time employees. The company went IPO on 2021-08-17. The firm is focused on developing therapies for the local treatment of solid tumors. The firm's lead product candidate RenovoGem. Its other product candidate include Renovo Trans-Arterial Micro-Perfusion (RenovoTAMP), and RenovoCath delivery system. RenovoGem, is a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath. Its therapy platform, RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) is focused on optimizing drug concentration in solid tumors using small molecule chemotherapeutics that enable physicians to isolate segments of the vascular anatomy closest to tumors and force chemotherapy across the blood vessel wall to bathe these difficult-to-reach tumors in chemotherapy.

RNXT Intrinsic Value
5.6 USD
Undervaluation 77%
Intrinsic Value
Price
Back to Top